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ABSTRACT
A Comparison of Spatio-Temporal Prediction Methods of
Cancer Incidence in the U.S.
by
Michelle Hamlyn
Dr. Kaushik Ghosh, Examination Committee Chair
Assistant Professor of Biostatistics
University of Nevada, Las Vegas
Cancer is the cause of one out of four deaths in the United States, and in 2009,
researchers expected over 1.5 million new patients to be diagnosed with some form
of cancer. People diagnosed with cancer, whether a common or rare type, need to
undergo treatments, the amount and kind of which will depend on the severity of
the cancer. So how do healthcare providers know how much funding is needed for
treatment? What would better enable a pharmaceutical company to determine how
much to allocate for research and development of drugs, the amount of each drug
to manufacture, or the time spent to improve or reformulate those drugs? How do
government planners determine which cancers need more attention than others? To
answer these questions, it becomes extremely important to get accurate predictions
iii
of new cancer cases (also known as cancer incidences) that will occur in the future
based on past data.
Past data on cancer incidences in the U.S. is available only at certain cancer
registries. These registries did not all come online at the same time, resulting in
varying lengths of incidence data. Prediction into the future would require one to
account for these varying lengths. Additionally, since these registries do not cover
the entire United States, one needs to incorporate some spatial projection methods.
In this thesis, we develop a Bayesian spatio-temporal method of predicting future
cancer incidences based on past data. A conditional autoregressive prior is used for
the spatial component and an autoregressive model is used for the temporal part. We
use standard Bayesian Markov chain Monte Carlo techniques to develop predictions
four years into the future for individual states. The method is illustrated using
incidence data for some rare and common cancers.
iv
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CHAPTER 1
INTRODUCTION
1.1 Introduction
Cancer is the cause of one out of four deaths in the United States, and, in 2009,
researchers expected over 1.5 million new patients to be diagnosed with some form of
cancer [2]. According to the Centers for Disease Control and Prevention, breast cancer
and lung cancer are two of the most common cancers. Based on rates from 2005 to
2007, the National Cancer Institute reported that one in eight women in the U.S. will
be diagnosed with breast cancer in their lifetime [4]. In 2010, the American Cancer
Society estimated that there would be about 222,520 new cases of lung cancer, the
second most common cancer [3]. The rates from 2005 to 2007 lead experts to expect
that almost seven percent of men and women will be diagnosed with lung cancer in
their lifetime [9]. On the other side of the spectrum, less than half a percent of the
population born today will be diagnosed with cancer of the small intestine. Hence
the number of cancer cases diagnosed can vary widely.
People diagnosed with cancer, whether an ordinary or rare type, need to undergo
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treatments, the amount and kind of which will depend on the severity of the can-
cer. So how do healthcare providers know how much funding is needed for future
treatment? What would better enable a pharmaceutical company to determine how
much to allocate for research and development of drugs, the amount of each drug
to manufacture, or the time spent to improve or reformulate those drugs? How do
government planners determine which cancers need more attention than others?
To answer these questions, it becomes extremely important to get accurate pre-
dictions of new cancer cases (also known as cancer incidence) that will occur in the
future. Statisticians continue to search for models that will accurately predict future
cancer incidences based on historical data and allow healthcare providers to set aside
a reasonable amount of funding for research, detection, and treatment of new cases
[13]. The main focus of this thesis will be to use observed incidence data to project
future counts for the entire U.S.
1.2 Data
Currently, data on cancer incidence is collected at several cancer registries, which
are spread across the United States and cover only a small fraction of the total
population. The data for this study was obtained from registries affiliated with the
National Cancer Institute’s Surveillance, Epidemiology and End Results program,
henceforth to be called SEER registries. The SEER program has been collecting
incidence data since 1973, when it started with seven registries [10]. Over the years,
it has grown to its current size of seventeen registries shown in the map in Figure 1.1.
2
Since not all registries went online at the same time, some registries have thirty years
worth of data while others may have only ten.
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Figure 1.1: U.S. map showing the 17 SEER registries.
Currently, the incidence and survival data published by SEER covers about twenty-
eight percent of the U.S. population and includes many demographics, such as race,
which includes African American, Hispanic and Asian subgroups. Among the rou-
tinely collected data for each incidence, SEER is the only program in the U.S. to
include the stage of cancer at the time of diagnosis. Not only does SEER allow
access to the data for analysis by different organizations, it is also committed to con-
tinually improving methods so that complete and accurate data are collected. The
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program’s goals, statistics, data and information for registrars can be found on the
SEER website, http://seer.cancer.gov/ [8].
The SEER data used in this study provided incidences for seventeen different
registries broken down by cancer type. SEER collects data on new cases as well as
other variables such as whether the person was a smoker or had a family history of
cancer. For this study we have used only the incidence counts to keep our model
simple.
Some registries had collected data for the whole state, while some were focused
on specific locations. For example, California had four different registries: one for
the Los Angeles area, one for the San Jose area, one for San Francisco and Oakland
and the last one collected data for the remaining part of California. Unfortunately,
these registries were not all online at the same time, so we were unable to get a
clear picture on total California incidences. To simplify our model, we decided to
study only states that had a single registry collecting data anytime between 1973 and
2003. Those nine states were Connecticut, Hawaii, Iowa, New Mexico, Utah, Alaska,
Kentucky, Louisiana and New Jersey. Although this may seem like a small sample,
these registries provide valuable information on cancer incidences across the country.
For this study, we have chosen to focus and test our model on two common
cancers – breast and lung cancer, and one rare type – cancer of the small intestine.
The original data can be seen in Tables 5.1 - 5.3 in the Appendix. As can be seen
in Figure 1.2 and Figure 1.3, the number of new breast and lung cancer cases has for
the most part been increasing over the years, although a slight decline can be seen
after 2000. Three of the four states from the west side of the country – New Mexico,
4
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Figure 1.2: SEER data for breast cancer incidence from 1973 to 2003.
Utah and Hawaii – have close to the same number of new cases each year. However,
based on Figure 1.2 and Figure 1.3, we could not conclude that region alone drives
the number of new incidences, since New Jersey has a significantly higher number
of incidences even though it is in closer proximity to Connecticut than Hawaii is to
Utah or New Mexico.
In Figure 1.4, the number of new small intestine cancer cases show an overall
increase, but in general from year to year, seems to fluctuate between increasing and
decreasing more than the breast and lung cancer incidences. As we saw with the
other cancer types, the incidences for cancer of the small intestine in New Jersey are
also significantly higher than those in the other regions.
As can be seen in all figures, not all states had observed incidences every year.
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Figure 1.3: SEER data for lung cancer incidence from 1973 to 2003.
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Figure 1.4: SEER data for small intestine cancer incidence from 1973 to 2003.
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Due to the incomplete and irregular nature of the past data, incidence prediction
presents several challenges. First, in any particular year, incidence data are available
only at the SEER registries, leaving counts outside those locations unobserved. This
requires some sort of spatial projection to “fill-in” the unobserved sites. Next, the
data need to be temporally projected. Some feel that any incomplete data should
just be removed. However, this can lead to a loss of power and in our case would
remove almost twenty years worth of data [13]. Therefore, we plan to research and
investigate methods for projecting future incidence counts in the SEER as well as the
unobserved non-SEER regions and then compare them to methods currently being
used by the American Cancer Society (ACS).
1.3 Past Work
Currently, ACS is responsible for incidence projection using a two step method as
follows. First, for any year, it spatially extrapolates the incidence counts to non-
SEER regions. To estimate the incidences for every state in that particular year,
ACS assumes that the number of new cases in county i and age-group j has a Poisson
distribution with the intensity λi,j having the following log-linear structure
ln(λij|α, β, γ, δ, ζ) = αr + f(aj)β + ln(mij)γ +X ′iδ + Y ′i ζ,
where αr is the intercept for region r (r = 1, 2, 3, 4) where county i is located, and aj is
the centered midpoint for age group j. To accommodate potential downturns in cancer
rates among older patients, f(aj) was taken to be a cubic function of age aj. The
mortality rate is represented by mij and the vectors Xi and Yi represent demographic
7
covariates and lifestyle covariates respectively [11]. Next, the output from the spatial
projection is used in a temporal model that projects incidence counts four years
into the future. Based on a study that compared four different types of temporal
methods, ACS determined that a piecewise linear regression method, also known as
a joinpoint method, was most accurate [10]. For observations (x1, y1), · · · , (xn, yn)
with x1 ≤ · · · ≤ xn, the general joinpoint model can be written as [6]
E(y | x) = β0 + β1x+ δ1(x− τ1)+ + · · ·+ δk(x− τk)+,
where τk’s are unknown joinpoints and
a+ =

a when a > 0,
0 otherwise.
Although the ACS determined it to be the best method for projecting new cases
in SEER and non-SEER regions, there are several drawbacks to this method, the
biggest one being that one must use two separate methods to model the spatial and
temporal components. As a result, it is difficult to provide accurate measures of
overall uncertainty for the projected counts.
Therefore, our primary goal in this project will be to combine the spatial and
temporal estimation into one single model and study the effectiveness of the proposed
model. For simplicity, we will only use observed incidence counts as inputs to our
model and ignore other covariates such as mortality counts, average income, etc.
In Chapter 2, we propose a temporal prediction model to be fitted using Bayesian
techniques and apply it to the three cancers in Chapter 3. A spatial improvement
is introduced and tested in Chapter 4. Finally, we compare our predictions for the
8
year 2006 to some of the predictions published by the ACS and also discuss further
research.
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CHAPTER 2
A TEMPORAL PROJECTION MODEL
2.1 Introduction
As previously mentioned, SEER started in 1973 with seven registries and over the
years has grown to its current size of seventeen registries. Not all affiliated registries
came online at the same time, giving rise to an incomplete data problem. Below we
propose a model that is able to accommodate vectors of different data lengths and
use it to generate predictions.
Consider a specific cancer. Let Yi,t be the incidence count in state i at time t and
yi,t be its observed counterpart. We assume that the time series of incidence counts
for each state is driven by a common underlying time series xt with state-specific
multipliers of θi. Let Yi = (yi,1, · · · , yi,n), X = (x1, · · · , xn) and σ2 be the variance.
We assume Yi,t∼N(θixt, σ2). For the five states with data for all thirty-one years,
(Connecticut, Hawaii, Iowa, New Mexico, and Utah) the likelihood contribution for
state i is
f(Yi|X, θi, σ2) = f(yi,1|θi, x1, σ2) · · · f(yi,n|θi, xn, σ2),
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where i = 1, 2, 3, 4, 5 and n = 31. Alaska did not start recording incidences until
1992, so its conditional distribution only had twelve years of data and therefore its
likelihood contribution is of the form
f(Y6|X, θ6, σ2) = f(y6,t0+1|θ6, xt0+1, σ2) · · · f(y6,n|θ6, xn, σ2),
where t0 = 19. The remaining three states, Kentucky, Louisiana and New Jersey only
began collecting data in 2000 so they could only contribute four years of data and in
general their likelihood contribution looks like
f(Yi|X, θi, σ2) = f(yi,t0+9|θi, xt0+9, σ2) · · · f(yi,n|θi, xn, σ2),
for i = 7, 8, 9.
We now focus on the prior distribution of the model parameters, X, θ1, · · · , θ9 and
σ2. As a first pass, we assume that for t = 1, 2, · · · , n,
Xt∼N(xt−1, τ 2),
so we expect the conditional on the value at the current year to be the same as the
current value. The joint distribution of X then looks like
f(X|x0, τ 2) = f(x1|x0, τ 2)f(x2|x1, τ 2) · · · f(xn|xn−1, τ 2).
We also assume that the state-specific factors θi are independent of each other as well
as the underlying process X. Hence,
f(X, θ1, · · · , θ9, σ2|x0, τ 2) = f(X|x0, τ 2)f(θ1) · · · f(θ9)f(σ2).
Then the joint distribution of all the variables is
f(Y,X, θ1, · · · , θ9, σ2, x0, τ 2)
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= f(Y|X, θ1, · · · , θ9, σ2)f(X, θ1, · · · , θ9, σ2|x0, τ 2)f(x0, τ 2).
The joint distribution can be used to obtain the posterior distribution of the model
parameters. Since there is no explicit closed-form expression, a Markov chain Monte
Carlo approach will be used to sample from the posterior distribution. In particular,
a Gibbs sampler will be used, as the univariate posterior conditionals have simple
closed-form expressions. In order to calculate the full conditional distributions, the
prior information had to first be identified and are as follows:
σ2∼IG(a1, b1),
where a1 and b1 are known,
τ 2∼IG(a2, b2),
where a2 and b2 are known,
X0∼N(µ0, w2),
with µ0 and w
2 both known, and θi has a non-informative prior
f(θi) = constant.
Here we use N to denote the normal distribution and IG to denote the Inverse Gamma
distribution which has a pdf of
f(x|a, b) = (1/b)
a
Γ(a)
y−a−1exp
{
−1/b
y
}
,
for y > 0.
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2.2 Posterior Sampling
The univariate conditional posterior distributions for each parameter can be obtained
from the joint distribution in the previous section. Beginning with X, which allows
us to account for the time dependency for new incidences, the posterior conditional
distribution for Xt where t = (1, · · · , n− 1) is obtained as
f(xt| · · · ) ∝
exp
{
− 1
2σ2
m∑
i=1
(yi,t − θixt)2
}
exp
{
− 1
2τ 2
(xt+1 − xt)2
}
exp
{
− 1
2τ 2
(xt − xt−1)2
}
,
with m equal to the total number of states and f(xt| · · · ) denoting the distribution
of Xt given all other quantities. That is,
Xt| · · · ∼N
(∑m
i=1 yi,tθi
σ2
+ xt+1+xt−1
τ2∑m
i=1 θ
2
i
σ2
+ 2
τ2
,
(∑m
i=1 θ
2
i
σ2
+
2
τ 2
)−1)
.
Similarly the distribution of Xn is
Xn| · · · ∼N
∑9i=1 yi,nθiσ2 + xn−1τ2∑9
i=1 θ
2
i
σ2
+ 1
τ2
,
(∑9
i=1 θ
2
i
σ2
+
1
τ 2
)−1 .
The posterior conditional distribution for X0 is
X0| · · · ∼N
(
x1
τ2
+ µ0
w2
1
τ2
+ 1
w2
,
(
1
τ 2
+
1
w2
)−1)
.
For θi (i = 1, 2, 3, 4, 5) we have
θi| · · · ∼N
(∑n
t=1 yi,txt∑n
t=1 x
2
t
,
σ2∑n
t=1 x
2
t
)
.
As previously mentioned, four states had less than thirty-one years of observed data
so the posterior reflected only the years for which data was collected. For θ6 (corre-
sponding to Alaska) which had data for the years t0 + 1, t0 + 2, · · · , n, the posterior
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had the following normal distribution
θ6| · · · ∼N
(∑n
t=t0+1
y6,txt∑n
t=t0+1
x2t
,
σ2∑n
t=t0+1
x2t
)
.
Only four years worth of data was available for Kentucky, Louisiana, and New
Jersey corresponding to θ7, θ8 and θ9 but they still had similar distributions which in
general can be shown to be
θi| · · · ∼N
(∑n
t=t0+9
yi,txt∑n
t=t0+9
x2t
,
σ2∑n
t=t0+9
x2t
)
,
where i = 7, 8, 9. Finally, for the variances, σ2 and τ 2, the posteriors had Inverse
Gamma distributions. For σ2, we have
σ2| · · · ∼IG(a∗1, b∗1),
where
a∗1 =
9n− 4t0 + 24
2
+ a1,
and
b∗1 =
{
1
2
5∑
i=1
n∑
j=1
(yi,j − θixj)2 + 1
2
n∑
i=t0+1
(y6,j − θ6xj)2 + 1
2
n∑
i=t0+9
9∑
j=7
(yi,j − θixj)2 + 1
b1
}−1
and for τ 2 we have ,
τ 2| · · · ∼IG
(
n
2
+ a2,
{
1
b2
+
∑
(xi − xi−1)
2
}−1)
.
The Gibbs sampler samples each parameter from its conditional posterior distri-
bution and generates a dependent sequence that eventually converges to the joint
posterior distribution of interest. For example, if at the sth iteration, the parameter
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values are given by (x(s), σ(s)
2
, τ (s)
2
, θ(s)), the next iteration of parameter values will
be obtained by generating θ(s+1) from
p(θ|y,x(s), σ(s)2 , τ (s)2),
X(s+1) from
p(x|y,θ(s+1), σ(s)2 , τ (s)2),
σ(s+1)
2
from
p(σ2|y,θ(s+1),x(s+1), τ (s)2),
and τ (s+1)
2
from
p(τ 2|y,θ(s+1),x(s+1), σ(s+1)2).
This process is repeated for each parameter until the Gibbs sampler converges.
2.3 Predictions
Once the Gibbs sampler has converged, predictions into the future could be made
based on samples drawn from the posterior. Suppose we want to predict new in-
cidences for Connecticut in 2004, based on data from 1973 to 2003. Then we are
essentially looking for a 1-year-ahead prediction. The prediction will be given by the
mean of the one-year-ahead predictive density. In general, if Y represents all available
prior year data, we will denote the one-year-ahead prediction for region i by Yˆi,n+1
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which will be calculated as
E(Yi,n+1|Y) =
∫
yi,n+1f(yi,n+1|y)dyi,n+1
=
∫ ∫ ∫
yi,n+1f(yi,n+1|θi, xn+1,y)f(θi, xn+1|y)dyi,n+1dθidxn+1 (2.1)
=
∫ ∫
θixn+1f(θi, xn+1|y)dθidxn+1 (2.2)
=
∫ ∫
θixn+1f(θi, xn+1|y)dθidxn+1
=
∫ ∫ ∫
θixn+1f(θi, xn+1, xn|y)dθidxn+1dxn
=
∫ ∫ ∫
θixn+1f(xn+1|xn, θi,y)f(θi, xn|y)dθidxn+1dxn
=
∫ ∫
θixnf(θi, xn|y)dθidxn
= E(θiXn|y),
where we move from Step (2.1) to Step (2.2) using
Yi,n+1|θi, Xn+1∼N(θixn+1, σ2).
Then E(θiXn|y) can be approximated by
1
M
M∑
m=1
θ
(m)
i x
(m)
n ,
where M is equal to the total number of iterations of the Gibbs sampler.
Using the same principle, the two-year-ahead prediction for state i, denoted by
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Yˆi,n+2 will be calculated as
Yˆi,n+2 = E(Yi,n+2|Y)
=
∫
yi,n+2f(yi,n+2|y)dyi,n+2
=
∫ ∫ ∫
yi,n+2f(yi,n+2|θi, xn+2,y)f(θi, xn+2|y)dyi,n+2dθidxn+2
=
∫ ∫
θixn+2f(θi, xn+2|y)dθidxn+2
=
∫ ∫ ∫
θixn+2f(θi, xn+2, xn+1|y)dθidxn+2dxn+1
=
∫ ∫ ∫
θixn+2f(xn+2|xn+1, θi,y)f(θi, xn+1|y)dθidxn+2dxn+1
=
∫ ∫
θixn+1f(θi, xn+1|y)dθidxn+1
=
∫ ∫ ∫
θixn+1f(θi, xn+1, xn|y)dθidxn+1dxn
=
∫ ∫ ∫
θixn+1f(xn+1|xn, θi,y)f(θi, xn|y)dθidxn+1dxn
=
∫ ∫
θixnf(θi, xn|y)dθidxn
= E(θiXn|y),
which is the same as the one-year-ahead prediction. Proceeding similarly, it can be
shown that Yˆi,n+k = E(Yi,n+k|Y) = E(θiXn|y) for k = 2, 3, · · · . That is, the k-year-
ahead prediction is the same for all k.
However the variance for each year will show how the uncertainty changes as
predictions are made further away from the last year observed. Consider the variance
for a one-year-ahead prediction for region i given by,
V ar(Yi,n+1|Y) = E(Y 2i,n+1|Y)− {E(Yin+1|Y)}2.
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First, we can reduce E(Y 2i,n+1|y) using the definition and integrating
E(Y 2i,n+1|y) =
∫
y2i,n+1f(yi,n+1)dyi,n+1
=
∫ ∫ ∫
y2i,n+1f(yi,n+1|θi, xn+1,y)f(θi, xn+1|y)dθidxn+1dyi,n+1
=
∫ ∫ ∫
y2i,n+1f(yi,n+1|θi, xn+1)f(θi, xn+1|y)dθidxn+1dyi,n+1. (2.3)
Now
∫
y2i,n+1f(yi,n+1|θi, xn+1)dyi,n+1
= V ar(yi,n+1|θi, xn+1) + {E(yi,n+1|θi, xn+1)}2
= σ2 + (θixn+1)
2,
since Yi,n+1|θi, xn+1∼N(θixn+1, τ 2).
Then (2.3) becomes
∫ ∫ ∫
y2i,n+1f(yi,n+1|θi, xn+1,y)f(θi, xn+1|y)dθidxn+1dyi,n+1
=
∫ ∫
(σ2 + θ2i x
2
n+1)f(θi, xn+1|y)dθidxn+1
= σ2 +
∫ ∫
θ2i x
2
n+1f(θi, xn+1|y)dθidxn+1
= σ2 +
∫ ∫
θ2i x
2
n+1f(xn+1|θi,y)f(θi|y)dxn+1dθi
= σ2 +
∫ ∫ ∫
θ2i x
2
n+1f(xn+1|θi, xn,y)f(xn|θi,y)f(θi|y)dxn+1dxndθi
= σ2 +
∫ ∫ ∫
θ2i x
2
n+1f(xn+1|xn)f(xn|θi,y)f(θi|y)dxn+1dxndθi.
We know by definition that
∫
x2n+1f(xn+1|xn)dxn+1 = E(X2n+1|xn),
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which can be broken down into
V ar(Xn+1|xn) + {E(Xn+1|xn)}2,
which is equal to
τ 2 + x2n,
since
Xn+1|Xn∼N(Xn, τ 2).
Therefore,
σ2 +
∫ ∫ ∫
θ2i x
2
n+1f(xn+1|xn)f(xn|θi,y)f(θi|y)dxn+1dxndθi
= σ2 +
∫ ∫
θ2i (τ
2 + x2n)f(xn|θi,y)f(θi|y)dxndθi
= σ2 + τ 2
∫ ∫
θ2i f(xn|θi,y)f(θi|y)dxndθi +
∫ ∫
θ2i x
2
nf(xn|θi,y)f(θi|y)dxndθi
= σ2 + τ 2E(θ2i |y) + E(θ2i x2n|y).
Next,
{E(Yi,n+1|y)} =
∫
yi,n+1f(yi,n+1|y)dyi,n+1
=
∫ ∫ ∫
yi,n+1f(yi,n+1|θi, xn+1,y)f(θi, xn+1|y)dθidxn+1dyi,n+1. (2.4)
Since Yi,n+1|θi, xn+1∼N(θixn+1, σ2), we have Equation (2.4) equal to,∫ ∫ ∫
yi,n+1f(yi,n+1|θi, xn+1,y)f(θi, xn+1|y)dθidxn+1dyi,n+1
=
∫ ∫
θixn+1f(θi, xn+1|y)dθidxn+1
=
∫ ∫ ∫
θixn+1f(θi, xn+1, xn|y)dθidxn+1dxn
=
∫ ∫ ∫
θixn+1f(xn+1|xn, θi,y)f(xn, θi|y)dθidxn+1dxn.
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Since Xn+1|xn∼N(xn, τ 2), we have
∫ ∫ ∫
θixn+1f(xn+1|xn, θi,y)f(xn, θi|y)dθidxn+1dxn
=
∫ ∫
θixnf(xn, θi|y)dθidxn,
which by definition is equal to E(θiXn|y). Therefore,
V ar(Yi,n+1|y) = σ2 + τ 2E(θ2i |y) + E(θ2iX2n|y)− {E(θiXn|y)}2,
which can be approximated by
1
M
M∑
m=1
σ(m)
2
+
1
M
M∑
m=1
τ (m)
2
θ
(m)2
i +
1
M
M∑
m=1
θ
(m)2
i x
(m)2
n −
(
1
M
M∑
m=1
θ
(m)
i x
(m)
n
)2
.
In a similar manner, we can obtain expressions for the variances for the two-year-
ahead and three-year-ahead predictions. In general, for k-year-ahead predictions, we
will have
V ar(Yi,n+k|Y) = σ2 + kτ 2E(θ2i |y) + E(θ2iX2n|y)− {E(θiXn|y)}2,
which can be approximated by
1
M
M∑
m=1
σ2(m) + k(
1
M
M∑
m=1
τ 2(m)θ
(m)2
i ) +
1
M
M∑
m=1
θ
(m)2
i x
(m)2
n − (
1
M
M∑
m=1
θ
(m)
i x
(m)
n )
2.
Since the parameters and their distributions have all been identified, we can now run
our model and begin making predictions.
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CHAPTER 3
TESTING THE MODEL
3.1 Predictions
We applied the model developed earlier to the three data sets. First, we ran the Gibbs
sampler in R to get samples from posterior distributions and then used the posterior
samples to approximate the expected values found in Chapter 2 to make predictions
for 2001 to 2003. The predictions were then compared to the observed values by
finding a quantile interval for the prediction. Observed values that fell within the
interval were considered “good” predictions.
We used the following prior distributions for model parameters as outlined in
Chapter 2:
σ2∼IG
(
2.01,
1
1.01
)
,
and
τ 2∼IG
(
2.01,
1
1.01
)
.
These choices reflect uncertainty in the prior information and were guided by the fact
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that if X∼IG(a, b) we have
E(X) =
1
b(a− 1) ,
and
V ar(X) =
1
{b(a− 1)}2(a− 2) ,
when a > 2. We also chose
X0∼N(0, 5000),
where the large variance was choosen to make up for the uncertainty of X0. State-
specific θi–values were chosen to have a non-informative prior
f(θi) = constant,
again to reflect uncertainty in prior information.
We used the data from each state to get starting values for θ and X. Since X
represents year-to-year dependency over all the states, the starting value for X was
estimated at the mean number of incidences at each year. Then θ was estimated
using the mean number of incidences per state divided by the mean of the xt starting
values. The starting values for τ 2, σ2 and X0 were randomly drawn from the prior
distributions mentioned previously.
The Gibbs sampler was coded in R. It was run for 25,000 iterations and the first
500 iterations were discarded since the sampler had not yet converged. Convergence
was verified using traceplots where the parameter values were plotted against the
iteration number for each parameter σ2 and τ 2. When looking at the traceplot of θi
and xt they show non-convergence due to lack of identifiability but a plot of θixt for
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Figure 3.1: Convergence check for Gibbs sampler to predict 2001-2003.
i = 1, 2, · · · , 9 and t = 1, 2, · · · , 28 showed convergence. Figure 3.1 shows an example
of the traceplots when the sampler converged. One should not be able to identify
a pattern; that is we expect to see a line jumping back and forth but no obvious
increase or decrease.
The model was then tested using lung, breast and small intestine cancer data.
We used our model to predict for 2001 based on data from 1973 to 2000 and then
compared those predictions to the observed counts. As can be seen in Table 3.1, for
lung cancer, the model seems to be most often under-predicting. To determine if the
difference between the prediction and the actual count is significant, we should look
at a prediction interval.
Based on the variances discussed in Chapter 2 the approximate 95% prediction
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Table 3.1: 2001 Observed and predicted lung cancer incidences for 2001 using data
up to 2000.
State Prediction Observed Difference
CT 2539 2529 10
HI 576 611 -35
IA 2206 2174 32
NM 700 813 -113
UT 427 503 -76
AK 46 53 -7
KY 4142 4263 -121
LA 3422 3494 -72
NJ 6024 6065 -41
intervals Yˆi,n+1 ± 1.96
√
V ar(Yi,n+1|Y ) should also show how the uncertainty changes
as we predict further ahead. However, as the samples of σ2 were very large as shown
in Figure 3.2, the prediction intervals constructed in this fashion were not practically
useful.
Therefore it was decided to calculate the 2.5% and 97.5% quantiles for each pre-
diction since this would give us similar results as using an interval two standard
deviations from the mean. Table 3.2, Table 3.3 and Table 3.4 show the predicted
value along with the 95% interval and the observed incidences for 2001, for three
different cancers. As we can see, the observed incidences fall within the interval in
over half the states for each cancer type. The observed incidences for New Mexico
24
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Figure 3.2: Boxplot of a sample of 100 iterations of σ2.
Table 3.2: Predictions of breast cancer incidences for 2001 using data up to 2000.
State 2.5% Quantile Prediction 97.5% Quantile Observed
CT 2796 2917 3037 3026
HI 628 679 731 913
IA 2265 2368 2468 2291
NM 848 906 964 1125
UT 800 855 912 1095
AK -24 42 1086 46
KY 2654 2842 3034 2872
LA 2787 2975 3163 2906
NJ 6473 6662 6851 6725
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Table 3.3: Predictions of lung cancer incidences for 2001 using data up to 2000.
State 2.5% Quantile Prediction 97.5% Quantile Observed
CT 2476 2539 2601 2529
HI 551 576 601 611
IA 2149 2206 2261 2174
NM 673 700 727 813
UT 404 427 451 503
AK 14 46 78 53
KY 4047 4142 4239 4263
LA 3327 3422 3517 3494
NJ 5928 6024 6119 6065
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Table 3.4: Predictions of small intestine cancer incidences for 2001 using data up to
2000.
State 2.5% Quantile Prediction 97.5% Quantile Observed
CT 55 61 67 59
HI 12 15 18 17
IA 54 60 65 60
NM 17 20 23 33
UT 21 24 27 34
AK -2 1 4 3
KY 72 81 90 76
LA 72 81 90 91
NJ 139 148 157 169
27
and Utah did not fall within the interval for any type of cancer. Data for these two
states show some unusual fluctuations taking place beginning about 1995 and 1996
that aren’t happening in the other states. According to the observed values, there
seem to be some significant unexpected increases and decreases in the number of cases
which maybe causing some inaccuracies in our predictions.
Although this method does a decent job of predicting incidences, the predictions
are only falling in the intervals about half the time. As shown in Chapter 2, the mean
for the k-year-ahead prediction will be the same as the one-year-ahead prediction.
This is a strong limitation of the model since for most cancers we would expect to
see an increasing or decreasing trend. Since we weren’t able to use the variances
to calculate the prediction method, we no longer have the ability to see how the
uncertainty changes when two and three-year predictions are made. Therefore, this
model seems to only be useful for one-year-ahead predictions.
3.2 Modified Model
In an attempt to improve the predictions and see how the two- and three-year-ahead
predictions would change, we incorporated an autoregression coefficient φ into the
distribution of Xt. Starting with the original model tested
Yit∼N(θixt, σ2),
where we assumed
Xt∼N(xt−1, τ 2),
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we will now assume
Xt∼N(φxt−1, τ 2).
With the additional parameter φ, the posterior distributions in our Gibbs sampler
will need to be updated. The univariate posterior conditional distribution for Xt
where t = 1, 2, · · · , n− 1 becomes
Xt| · · · ∼N
∑9i=1 yi,tθiσ2 + φ(xt+1+xt−1)τ2∑9
i=1 θ
2
i
σ2
+ 1+φ
2
τ2
,
(∑9
i=1 θ
2
i
σ2
+
1 + φ2
τ 2
)−1 .
The posterior conditional of Xn is given by
Xn| · · · ∼N
∑9i=1 yi,nθiσ2 + φxn−1τ2∑9
i=1 θ
2
i
σ2
+ 1
τ2
,
(∑9
i=1 θ
2
i
σ2
+
1
τ 2
)−1 .
The posterior conditional distribution for X0 and τ
2 will also have slight modifications
as can be seen below. First, the posterior conditional of X0 is,
X0| · · · ∼N
(
φx1
τ2
+ µ0
w2
φ2
τ2
+ 1
w2
,
(
φ2
τ 2
+
1
w2
)−1)
.
Then the posterior conditional distribution for τ 2 will look like
τ 2| · · · ∼IG
(
n
2
+ a2,
(
1
b2
+
∑n
i=1(xi − φxi−1)2
2
)−1)
.
Finally, we will also need to update φ with each iteration. Assuming a non-informative
prior for φ, the posterior can be found using the definition and is equal to
f(φ| · · · ) ∝ f(x1|φ, x0, τ 2) · · · f(xn|φ, xn−1, τ 2)
∝ exp
{
− 1
2τ 2
∑
(x1 − φx0)2} · · · exp{− 1
2τ 2
∑
(xn − φxn−1)2
}
= exp
{
− 1
2τ 2
∑
(x21 − 2φx1x0 + φ2x20)
}
· · · exp
{
− 1
2τ 2
∑
(x2n − 2φxnxn−1 + φ2x2n−1)
}
= exp
{
−1
2
[
φ
(x1x0
τ 2
+ · · ·+ xnxn−1
τ 2
)
+ φ2
(
x20
τ 2
+ · · ·+ x
2
n−1
τ 2
)]}
.
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This gives us a posterior distribution of
N
(
x1x0 + x2x1 + · · ·+ xnxn−1
x20 + · · ·+ x2n−1
,
τ 2
x20 + · · ·+ x2n−1
)
.
With the addition of φ, predictions in general will be
Yˆi,n+k = E(Yi,n+k|Y) = E(θiφkxn|Y)
which is estimated using
E(θiφ
kxn|Y) ≈ 1
M
M∑
m=1
θ
(m)
i φ
(m)kx(m)n ,
where i represents the region, M is the number of iterations and k is number of years
ahead for which prediction is desired.
A histogram of posterior samples of φ for breast cancer data up to 2000 is presented
in Figure 3.3. The corresponding summary statistics are in Table 3.5. Since the 95%
credible interval does not include one, we can conclude that φ is actually greater than
one, supporting a growing trend for the incidence counts.
Table 3.5: Posterior summary of φ for breast cancer incidences.
Min 1st Qu. Median Mean 3rd Qu. Max
0.9867 1.0190 1.0220 1.0220 1.0250 1.0640
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Figure 3.3: Histogram of posterior samples of φ for breast cancer incidences. The
value of φ = 1 shown in red.
3.3 Modified Predictions
We next used our modified model to develop predictions and prediction intervals for
2001 to 2003. As before, we applied our method to the data on the three cancer sites.
For intervals, we continued to use the quantile-based method. Results are presented
in Tables 3.6 - 3.14.
When we look at the predictions for 2001, we can see that for each cancer, the ac-
tual incidence counts for at least five or six of the nine states fell within the prediction
interval. As we move further out and begin predicting two or three years ahead, the
predictions become less accurate for the common cancers. Looking at 2002, cancer of
the small intestine has just under half of the actual incidences within the prediction
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interval and for 2003, over half the states’ predictions fell in the interval. For New
Mexico and Utah, there was only one prediction that was within the prediction inter-
val. However, Kentucky, Louisiana, and New Jersey were fairly accurate considering
they had the least amount of data.
Table 3.6: Predictions of breast cancer incidences for 2001 using data up to 2000 and
the modified model.
State 2.5% Quantile Prediction 97.5% Quantile Observed
CT 2917 3047 3166 3026
HI 655 709 764 913
IA 2364 2473 2573 2291
NM 886 946 1005 1125
UT 834 893 952 1095
AK -26 44 112 46
KY 2710 2905 3098 2872
LA 2849 3041 3234 2906
NJ 6604 6807 7010 6725
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Table 3.7: Predictions of breast cancer incidences for 2002 using data up to 2000 and
the modified model.
State 2.5% Quantile Prediction 97.5% Quantile Observed
CT 2965 3113 3248 2824
HI 668 725 783 904
IA 2402 2527 2639 2278
NM 902 967 1030 1109
UT 850 913 975 1046
AK -26 45 115 46
KY 2765 2968 3172 2827
LA 2907 3107 3312 2889
NJ 6722 6956 7188 6479
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Table 3.8: Predictions of breast cancer incidences for 2003 using data up to 2000 and
the modified model.
State 2.5% Quantile Prediction 97.5% Quantile Observed
CT 3010 3182 3335 2693
HI 680 740 802 853
IA 2440 2582 2709 2121
NM 917 988 1057 1036
UT 864 933 1000 1018
AK -27 46 117 61
KY 2819 3033 3250 2761
LA 2962 3175 3395 2879
NJ 6832 7108 7382 6294
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Table 3.9: Predictions of lung cancer incidences for 2001 using data up to 2000 and
the modified model.
State 2.5% Quantile Prediction 97.5% Quantile Observed
CT 2540 2611 2680 2529
HI 566 592 620 611
IA 2205 2268 2329 2174
NM 691 720 748 813
UT 415 440 464 503
AK 14 48 80 53
KY 4117 4219 4321 4263
LA 3387 3485 3586 3494
NJ 6027 6135 6244 6065
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Table 3.10: Predictions of lung cancer incidences for 2002 using data up to 2000 and
the modified model.
State 2.5% Quantile Prediction 97.5% Quantile Observed
CT 2574 2659 2740 2613
HI 575 603 632 679
IA 2235 2310 2381 2196
NM 702 733 764 891
UT 422 448 474 478
AK 15 49 82 53
KY 4179 4297 4417 4244
LA 3439 3550 3664 3301
NJ 6110 6248 6389 6077
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Table 3.11: Predictions of lung cancer incidences for 2003 using data up to 2000 and
the modified model.
State 2.5% Quantile Prediction 97.5% Quantile Observed
CT 2606 2708 2805 2559
HI 583 615 646 695
IA 2263 2353 2438 2248
NM 711 747 782 787
UT 428 456 484 514
AK 15 50 83 53
KY 4235 4376 4521 4134
LA 3485 3615 3748 3397
NJ 6185 6364 6548 5888
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Table 3.12: Predictions of small intestine cancer incidences for 2001 using data up to
2000 and the modified model.
State 2.5% Quantile Prediction 97.5% Quantile Observed
CT 53 62 70 59
HI 12 15 18 17
IA 52 60 68 60
NM 16 20 23 33
UT 20 24 28 34
AK -2 1 4 3
KY 71 82 93 76
LA 71 82 93 91
NJ 135 150 165 169
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Table 3.13: Predictions of small intestine cancer incidences for 2002 using data up to
2000 and the modified model.
State 2.5% Quantile Prediction 97.5% Quantile Observed
CT 50 62 75 82
HI 12 15 19 26
IA 49 61 73 69
NM 16 20 25 32
UT 19 25 30 42
AK -2 1 4 2
KY 68 83 100 85
LA 67 83 100 89
NJ 126 152 179 180
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Table 3.14: Predictions of small intestine cancer incidences for 2003 using data up to
2000 and the modified model.
State 2.5% Quantile Prediction 97.5% Quantile Observed
CT 47 63 81 72
HI 11 16 21 27
IA 46 62 80 67
NM 15 20 27 34
UT 18 25 33 39
AK -3 1 4 0
KY 63 85 108 71
LA 63 85 108 86
NJ 117 154 195 181
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3.4 Discussion
It appears that the model is predicting more accurately for cancer of the small in-
testine, which seems unusual since we assumed a normal distribution, and for a rare
cancer, a Poisson distribution may be a more appropriate fit. It also appears that
predictions seemed better for the states with the least amount of prior year data.
Overall, the model with φ predicted slightly higher for the one-year-ahead predic-
tions than the model where φ = 1. For example, looking at breast cancer incidences
in Table 3.15, most of the predicted values using the modified model are closer to the
observed values than the original model where φ = 1. This supports our previous
conclusion that φ is greater than one. Then we can see the growing trend for incidence
counts when we look at the two and three-year ahead predictions. Note however that
the methods discussed so far do not allow one to predict incidences for those states
without prior data. We attempt to do so in the next chapter.
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Table 3.15: Prediction comparison of breast cancer incidences for 2001 using data up
to 2000.
State φ=1 Modified Model Observed
CT 2917 3047 3026
HI 679 709 913
IA 2368 2471 2291
NM 906 946 1125
UT 855 893 1095
AK 42 44 46
KY 2842 2905 2872
LA 2975 3041 2906
NJ 6662 6807 6725
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CHAPTER 4
ADDING THE SPATIAL COMPONENT
4.1 Spatial Model
The previous models did not take into account the spatial structure of the states. We
now incorporate such information to improve the predictions. This final piece will
also allow us to use information from neighboring states to help predict incidences
for states where data had not been collected. In addition, this will help improve
predictions of states with prior data by sharing of information.
We will look at incorporating neighborhood information using the intrinsic Gaus-
sian Markov random field (IGMRF) described in Rue and Held [12]. We will use the
idea of first-order IGMRFs on regular lattices. Let
θ = (θ1, · · · , θ51)
be the θ-paramters for the fifty states and District of Columbia. For neighboring
states i and j, we will assume normal “increments”
θi − θj∼N(0, η2).
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Assuming that “increments” are independent, the IGMRF model is given by
pi(θ) ∝
(
1
η2
)(p−1)/2
exp
{
− 1
2η2
∑
j∼i
(θi − θj)2
}
,
where p = 51 for our case and j∼i represents the unordered pairs of neighbors, with
two states defined as neighbors if they share a border. If we let
θ−i = (θ1, · · · , θi−1, θi+1, · · · , θp),
it follows tha t
θi|θ−i, η2∼N
(∑
j∼i θj
ni
,
η2
ni
)
,
where ni represents the number of neighbors of state i. If prior year data are available
for state i, the posterior conditional of θi is
f(θi| · · · ) ∝ exp
{
− 1
2σ2
n∑
t=1
(yi,t − θixt)2
}
exp
{
− ni
2η2
(
θi −
∑
j∼i θj
nj
)2}
,
which can be written in the form
exp
{
−a
∗
2
(
θi − b
∗
a∗
)2}
.
Therefore,
θi| · · · ∼N
(
b∗3
a∗3
,
1
a∗3
)
,
with
a∗3 =
∑
x2t
σ2
+
1
η2
ni,
and
b∗3 =
∑
yi,txt
σ2
+
1
η2
∑
j∼i
θj.
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If state i does not have prior year information, the posterior will be
N
(∑
j∼i θj
ni
,
η2
ni
)
.
Thus, for states with past data, θ values are updated based on the past data as well
as data from neighboring states. For states with no past data, θ values are updated
based on θ’s of those neighboring states only. The case could exist where state i
does not have prior year data and does not share a border with region j for all j; for
example an island. In this instance we would have a difficult time updating the value
of θi. However for our study, the only two states without neighbors are Alaska and
Hawaii but we do have data from prior years, so this situation did not arise.
4.2 Spatial Predictions
Since the code is now quite complex, the iterations are running slower and the chain
is taking longer to converge. Therefore, we updated the Gibbs sampler using 15, 000
iterations with the first 5, 000 iterations removed for burn-in. As before, we used
samples from the posterior distribution to get Yˆi,n+k as well as the 95% prediction
intervals. ACS predictions for 2006 were estimated using data up through 2002,
so our prediction results for 2006 use data up to 2002 as well. Prediction results,
ACS predictions and observed values provided by the National Cancer Institute are
presented in Table 4.1, Table 4.2, and Table 4.3.
Looking at the spatial predictions found in Tables 4.1 - 4.3, it seems that the
predictions are now relatively close to the predictions made by the ACS. For breast
cancer (shown in Table 4.1), states that had prior year data look good, and for some
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states (Hawaii, Louisiana and New Jersey), our model is performing better than the
ACS model. Similar results can be seen for lung cancer in Table 4.2. For cancer
of the small intestine, because it is a rare form of cancer, the results by state were
not published by ACS. When we compare our predictions with the observed values
in Table 4.3, there are a few cases where fairly significant variations can be seen.
It appears though that the predictions for cancer of the small intestine are more
consistent and accurate than the predictions for lung or breast cancer.
Overall, the addition of the spatial component has improved the predictions made
in Chapter 3. For states where we had prior year data, being able to use information
from neighboring states allowed us to make predictions that were comparable to the
ACS predictions, and in some cases predictions were better than those reported by
ACS. We were also able to use the neighboring region’s information to make fairly
accurate predictions for states that did not have prior year information. There are
still some states where significant departures can be seen between the predicted and
the observed values. For these cases, further research needs to be done to identify
weighted values by state that could be incorporated as part of our neighborhood
information.
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Table 4.1: 2006 spatial predictions of breast cancer inci-
dences for all states using data from 1973 to 2002.
State Observed ACS Pred Spatial Pred 2.5% Quan 97.5% Quan
Alabama 3226 3740 3693 -16788 23906
Alaska 342 310 47 -22 115
Arizona Missing 3740 1644 -13049 16175
Arkansas 1847 2030 2653 -13111 18226
California 22085 21200 2188 -15457 19913
Colorado 2863 2650 2507 -11037 16541
Connecticut 2860 2600 3195 3026 3358
Delaware 599 570 2291 -17438 21618
D.C. 436 470 2476 -20575 26080
Florida 12862 13360 2757 -23773 28933
Georgia 5474 5920 3472 -11402 17901
Hawaii 836 680 770 707 833
Idaho 921 940 2219 -12159 16925
Illinois 8843 9250 2473 -14450 18372
Indiana 3965 4680 2419 -16606 21036
Iowa 2156 2230 2584 2445 2718
Kansas 2011 2080 2076 -14560 19255
Continued on next page . . .
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Table 4.1: 2006 spatial breast predictions contd.
State Observed ACS Pred Spatial Pred 2.5% Quan 97.5% Quan
Kentucky 2979 3220 3059 2888 3228
Louisiana 2763 4000 3139 2963 3313
Maine 1107 1040 2339 -33362 35794
Maryland 3608 4310 2402 -13242 18351
Massachusetts 5083 4680 2466 -12701 18238
Michigan 6965 7070 2498 -17307 22299
Minnesota 3575 3070 2476 -14813 19919
Mississippi 1701 2290 2314 -13763 18407
Missouri 4041 4570 2087 -10733 14787
Montana 642 620 2386 -15958 20556
Nebraska 1263 1200 2334 -12347 16847
Nevada 1405 1660 2037 -12202 16459
New Hampshire 993 940 2120 -17800 22514
New Jersey 6489 8110 7112 6794 7402
New Mexico 1144 1090 1016 946 1089
New York 14211 14400 2353 -13207 17790
North Carolina 6299 6290 2434 -17503 22353
North Dakota 460 470 2701 -17240 21924
Ohio 7935 9610 2218 -14232 19196
Continued on next page . . .
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Table 4.1: 2006 spatial breast predictions contd.
State Observed ACS Pred Spatial Pred 2.5% Quan 97.5% Quan
Oklahoma 2455 2860 1955 -11238 15664
Oregon 2791 2810 1851 -15696 19091
Pennsylvania 9831 12320 2494 -11702 16459
Rhode Island 850 780 2763 -19872 25615
South Carolina 3027 3170 2418 -24910 30724
South Dakota 476 520 2581 -12366 17854
Tennessee 4166 4630 2458 -11987 17172
Texas 12750 13150 2040 -14159 18930
Utah 1153 1200 961 893 1031
Vermont 526 520 2575 -19033 24383
Virginia 5167 6080 2319 -12794 17434
Washington 4449 4000 2418 -21438 27668
West Virginia 1317 1400 2263 -14254 18878
Wisconsin Missing 4000 2646 -16066 21556
Wyoming 317 260 2063 -11962 16420
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Table 4.2: 2006 spatial predictions of lung cancer inci-
dences for all states using data from 1973 to 2002.
State Observed ACS Pred Spatial Pred 2.5% Quan 97.5% Quan
Alabama 3784 3530 3520 -33709 40379
Alaska 324 240 52 18 86
Arizona Missing 3140 1558 -25290 28183
Arkansas 2452 2350 2648 -25948 31040
California 16872 14900 2031 -30827 34319
Colorado 1995 1790 2556 -21829 27504
Connecticut 2631 2000 2768 2667 2869
Delaware 783 550 2259 -33985 38136
D.C. 340 290 2636 -39169 45596
Florida 15891 13280 2561 -45381 49411
Georgia 5734 4860 3227 -23368 29731
Hawaii 744 500 635 602 667
Idaho 756 670 2177 -24711 28624
Illinois 9012 7290 2429 -27641 31773
Indiana 4955 4620 2497 -31975 35992
Iowa 2283 1850 2401 2312 2489
Kansas 1960 1650 1979 -28375 33057
Continued on next page . . .
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Table 4.2: 2006 spatial lung predictions contd.
State Observed ACS Pred Spatial Pred 2.5% Quan 97.5% Quan
Kentucky 4345 3760 4529 4376 4684
Louisiana 3344 3170 3657 3528 3789
Maine 1256 1030 2358 -61514 64657
Maryland 3489 3320 2484 -25835 31043
Massachusetts 4505 4070 2817 -25176 31205
Michigan 7589 6240 2606 -33206 38771
Minnesota 2882 2610 2538 -29204 33927
Mississippi 2280 2200 2180 -26546 31123
Missouri 4914 4130 2028 -21392 24899
Montana 650 620 2290 -31204 35219
Nebraska 1142 1000 2359 -24356 28335
Nevada 1732 1520 1870 -23880 28037
New Hampshire 928 770 2088 -34323 39170
New Jersey 5975 4960 6503 6289 6713
New Mexico 871 820 778 742 815
New York 13004 9900 2628 -25785 30669
North Carolina 6798 5480 2446 -33395 38046
North Dakota 378 330 2333 -34030 37640
Ohio 9096 7900 2177 -28214 32569
Continued on next page . . .
51
Table 4.2: 2006 spatial lung predictions contd.
State Observed ACS Pred Spatial Pred 2.5% Quan 97.5% Quan
Oklahoma 3097 2560 1864 -22388 26614
Oregon 2554 2290 1647 -29747 32830
Pennsylvania 10432 8450 2524 -23250 27991
Rhode Island 822 680 3515 -37412 44992
South Carolina 3290 3040 2432 -47650 53410
South Dakota 524 440 2631 -24683 30464
Tennessee 5332 4680 2262 -23680 28799
Texas 12312 10780 2057 -27323 32576
Utah 542 480 472 443 501
Vermont 554 390 2718 -36288 41507
Virginia 4952 4840 2323 -25488 29864
Washington 4054 3540 2576 -40769 49034
West Virginia 2038 1640 2179 -27701 31995
Wisconsin Missing 3040 2743 -30961 36489
Wyoming 257 290 1960 -23656 27676
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Table 4.3: 2006 spatial predictions of small intestine can-
cer incidences for all states using data from 1973 to 2002.
State Observed Spatial Pred 2.5% Quan 97.5% Quan
Alabama 126 106 -369 580
Alaska Suppressed 1 -3 5
Arizona Missing 50 -290 391
Arkansas 66 76 -287 449
California 552 67 -349 494
Colorado 80 75 -235 393
Connecticut 86 84 63 108
Delaware 20 69 -386 535
D.C. Suppressed 72 -464 622
Florida 385 77 -529 686
Georgia 143 101 -237 455
Hawaii 26 21 16 28
Idaho 30 66 -275 408
Illinois 262 75 -304 452
Indiana 140 73 -361 513
Iowa 71 81 61 104
Kansas 59 59 -328 458
Continued on next page . . .
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Table 4.3: 2006 spatial small intestine predictions contd.
State Observed Spatial Pred 2.5% Quan 97.5% Quan
Kentucky 105 98 74 126
Louisiana 90 106 80 136
Maine 30 71 -732 867
Maryland 116 73 -288 440
Massachusetts 158 75 -277 433
Michigan 242 74 -380 545
Minnesota 123 74 -327 481
Mississippi 61 65 -300 443
Missouri 107 63 -229 367
Montana Suppressed 71 -358 498
Nebraska 62 70 -271 410
Nevada 38 63 -273 401
New Hampshire 24 64 -394 538
New Jersey 204 203 154 258
New Mexico 38 29 21 38
New York 457 72 -285 433
North Carolina 183 72 -384 528
North Dakota Suppressed 79 -385 544
Ohio 254 66 -327 461
Continued on next page . . .
54
Table 4.3: 2006 spatial small intestine predictions contd.
State Observed Spatial Pred 2.5% Quan 97.5% Quan
Oklahoma 74 57 -256 374
Oregon 74 57 -340 452
Pennsylvania 315 78 -241 409
Rhode Island 24 85 -446 632
South Carolina 104 71 -572 724
South Dakota 21 76 -274 425
Tennessee 121 70 -257 403
Texas 443 60 -314 453
Utah 32 35 26 45
Vermont Suppressed 77 -417 569
Virginia 141 70 -289 437
Washington 132 71 -492 659
West Virginia 45 67 -308 454
Wisconsin Missing 80 -343 515
Wyoming Suppressed 61 -264 397
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CHAPTER 5
CONCLUSION
In this thesis, we have attempted to develop a spatio-temporal model for projecting
U.S. cancer incidence counts into the future based on SEER registry data. Using
a normal distribution and making assumptions regarding prior distributions allowed
us to find conditional posterior distributions for θi (the effect of region i from year
to year), xt (which captures the dependency of counts for time t for all regions),
and the variance σ2. While first year predictions seemed realistic, this model did not
consistently provide a reasonable two or three-year-ahead predictions. The predictions
were then improved upon by the addition of the autoregressive variable φ into the
distribution of xt.
Finally, we found a way to incorporate the spatial structure of states by the
IGMRF model. Overall, with this addition, we saw an improvement in the predictions,
especially for small intestine cancer. Therefore, we can conclude that we have a
decent model that can predict cancer incidences for rare or common cancers across
the U.S. using prior year data when it is available. If prior year data are unavailable,
the model uses information from neighboring states to make predictions. As the
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ability to register new incidences becomes easier and more consistent from state to
state, researchers will continue to look for ways to improve the prediction of cancer
incidences.
To help enhance our model some further research could be done. For example,
had the data included other information such as ethnicity, smoking rate, etc., we may
have been able to use a regression model to improve our predictions. It is possible
that by knowing if the patient had a family history of cancer, was a smoker or was
exposed to other elements that increase the risk for cancer, we could determine if
there was a correlation between the variables and the number of new incidences. If a
relationship was found, it could also help the health care industry to better educate
the community on early detection and ways to avoid cancer causing risks.
As we mentioned in Chapter 1, not all the data provided from the SEER registry
was used in this study. Some of the registries were for major cities instead of the
entire state so this study used only the data collected for an entire state. Although
a registry for Atlanta may not give us a complete picture of cancer incidences in
Georgia, it would still provide some information and might allow a more accurate
prediction for Georgia as well as the neighboring states.
In the final model which incorporated the spatial component, we could also look
at the effect of the predictions when µ and η2 are updated. In Chapter 4 we let µi
equal the state mean and µj be the neighboring mean. We then assumed that µi was
equal to µj and did not change as θ converged. However, as the seen in Figure 1.2,
Figure 1.3 and Figure 1.4 there were significant differences in the number of incidences
between some states. Therefore, it seems reasonable that by identifying and updating
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the mean for each state we may improve our predictions.
Finally, a normal distribution was used throughout the model but since the cancer
incidences are count data, a Poisson model might better represent that data. Lawson
(2009) described a model by Besag (1975) which uses an autologistic model on binary
data in a spatiotemporal setting [7]. The model is able to capture spatial correlation
effects as well as allowing conditioning on time labeled neighborhood counts using a
pseudolikelihood. Such a model could be modified to use a Poisson distribution but
would need to be explored further.
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APPENDIX
SEER Incidence Data Used
Table 5.1: Breast cancer incidences from SEER registries
Year CT HI IA NM UT AK KY LA NJ
1973 1543 247 1411 311 365 NA NA NA NA
1974 1766 267 1542 413 388 NA NA NA NA
1975 1817 266 1451 358 391 NA NA NA NA
1976 1713 256 1426 217 384 NA NA NA NA
1977 1721 296 1448 432 382 NA NA NA NA
1978 1714 284 1475 442 422 NA NA NA NA
1979 1790 318 1523 424 473 NA NA NA NA
1980 1831 319 1540 461 432 NA NA NA NA
1981 1949 318 1606 479 459 NA NA NA NA
1982 1914 359 1518 488 464 NA NA NA NA
1983 2044 356 1612 521 549 NA NA NA NA
Continued on next page . . .
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Table 5.1: Breast cancer incidence contd.
Year CT HI IA NM UT AK KY LA NJ
1984 2183 401 1688 575 591 NA NA NA NA
1985 2293 466 1769 606 576 NA NA NA NA
1986 2273 530 1939 624 671 NA NA NA NA
1987 2502 536 2024 711 698 NA NA NA NA
1988 2538 534 2158 677 693 NA NA NA NA
1989 2482 556 2010 707 686 NA NA NA NA
1990 2629 593 2032 822 710 NA NA NA NA
1991 2578 614 2077 816 776 NA NA NA NA
1992 2574 628 2191 875 750 26 NA NA NA
1993 2596 683 2125 795 815 32 NA NA NA
1994 2667 655 2094 916 836 35 NA NA NA
1995 2623 699 2160 964 887 48 NA NA NA
1996 2772 704 2121 1030 868 47 NA NA NA
1997 2707 872 2226 1008 904 35 NA NA NA
1998 2895 905 2385 1069 1034 48 NA NA NA
1999 2950 878 2337 1161 1008 32 NA NA NA
2000 2869 783 2188 1118 1053 56 2842 2975 6662
2001 3026 913 2291 1125 1095 46 2872 2906 6725
2002 2824 904 2278 1109 1046 46 2827 2889 6479
Continued on next page . . .
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Table 5.1: Breast cancer incidence contd.
Year CT HI IA NM UT AK KY LA NJ
2003 2693 853 2121 1036 1018 61 2761 2879 6294
Table 5.2: Lung cancer incidence from SEER registries
Year CT HI IA NM UT AK KY LA NJ
1973 1344 264 1298 305 216 NA NA NA NA
1974 1443 268 1223 310 203 NA NA NA NA
1975 1512 261 1327 364 242 NA NA NA NA
1976 1615 288 1364 366 248 NA NA NA NA
1977 1635 365 1366 364 228 NA NA NA NA
1978 1704 339 1504 419 251 NA NA NA NA
1978 1704 339 1504 419 251 NA NA NA NA
1979 1805 348 1545 463 292 NA NA NA NA
1980 1895 355 1557 451 281 NA NA NA NA
1981 1921 358 1615 490 315 NA NA NA NA
1982 2009 432 1631 497 299 NA NA NA NA
1983 2029 376 1732 494 358 NA NA NA NA
1984 2121 464 1807 535 350 NA NA NA NA
1985 2070 414 1854 534 339 NA NA NA NA
Continued on next page . . .
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Table 5.2: Lung cancer incidence contd.
Year CT HI IA NM UT AK KY LA NJ
1986 2174 459 1898 571 358 NA NA NA NA
1987 2304 517 1978 598 374 NA NA NA NA
1988 2389 480 2051 638 346 NA NA NA NA
1989 2388 488 2013 599 331 NA NA NA NA
1990 2359 563 1993 688 395 NA NA NA NA
1991 2485 568 2076 637 393 NA NA NA NA
1992 2414 595 2173 707 418 31 NA NA NA
1993 2405 598 2148 685 440 49 NA NA NA
1994 2383 580 2164 729 453 50 NA NA NA
1995 2485 593 2131 723 434 53 NA NA NA
1996 2521 623 2274 728 440 45 NA NA NA
1997 2480 658 2228 808 458 50 NA NA NA
1998 2628 672 2226 791 487 48 NA NA NA
1999 2483 687 2196 807 523 40 NA NA NA
2000 2459 650 2225 830 435 48 4142 3422 6024
2001 2529 611 2174 813 503 53 4263 3494 6065
2002 2613 679 2196 891 478 53 4244 3301 6077
2003 2559 695 2248 787 514 53 4134 3397 5888
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Table 5.3: Small intestine cancer incidence from SEER
registries
Year CT HI IA NM UT AK KY LA NJ
1973 31 6 25 6 6 NA NA NA NA
1974 32 5 38 11 13 NA NA NA NA
1975 28 2 39 6 10 NA NA NA NA
1976 34 9 22 11 8 NA NA NA NA
1977 22 4 26 7 11 NA NA NA NA
1978 26 9 21 11 7 NA NA NA NA
1979 22 6 35 10 8 NA NA NA NA
1980 36 8 27 9 10 NA NA NA NA
1981 34 5 39 2 6 NA NA NA NA
1982 37 6 38 8 15 NA NA NA NA
1983 35 7 38 10 9 NA NA NA NA
1984 39 6 35 11 13 NA NA NA NA
1985 31 11 36 15 9 NA NA NA NA
1986 43 5 35 9 23 NA NA NA NA
1987 47 11 49 10 9 NA NA NA NA
1988 45 12 46 18 21 NA NA NA NA
1989 41 10 52 18 16 NA NA NA NA
Continued on next page . . .
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Table 5.3: Small intestine cancer incidence contd.
Year CT HI IA NM UT AK KY LA NJ
1990 46 5 35 14 9 NA NA NA NA
1991 66 22 46 19 17 NA NA NA NA
1992 47 15 49 18 17 0 NA NA NA
1993 49 17 44 14 23 1 NA NA NA
1994 51 15 42 16 23 0 NA NA NA
1995 50 18 63 16 31 0 NA NA NA
1996 49 13 48 21 19 0 NA NA NA
1997 73 20 63 19 36 2 NA NA NA
1998 67 7 60 25 26 2 NA NA NA
1999 74 21 80 27 30 0 NA NA NA
2000 55 15 58 22 33 0 81 81 148
2001 59 17 60 33 34 3 76 91 169
2002 82 26 69 32 42 2 85 89 180
2003 72 27 67 34 39 0 71 86 181
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R Code
library(MCMCpack) #for rinvgamma function
rivg<-function(a, b){
rinvgamma(1, a, 1/b)
}
##data
d <- read.table("BreastNY.txt", header=TRUE)
d <- d[1:30,] #only used for testing predictions
#MH 04.28
#neighborhood matrix
n.m <- read.table("StateMatrix3.txt",header=TRUE)
c.mean=apply(d, 2, mean, na.rm=T)
c.var=apply(d, 2, var, na.rm=T)
r.mean = apply(d, 1, mean, na.rm=T)
r.var = apply(d, 1, var, na.rm=T)
#means used to calc starting values for x & theta
n <- nrow(d)
set.seed(1)
#these lines generate the initial values of the parameters x0,
tau^2, sigma^2, x1 - x19, theta1 - theta9
mu.0 <- 0
65
t.0 <- 19
a<-2.01; b<-1/1.01
t.2 <- rivg(a,b) #tau^2
s.2 <- rivg(a,b) #sigma^2
w.2 <- 5000 #var for w^2
eta.2 <- 5000
phi <- 1
r = n+1
x.0 <- rnorm(1,mu.0,sqrt(w.2))
x <- c(x.0, r.mean)
theta <- c.mean/mean(r.mean)
#starting values for theta
#MH 04.28
theta.n <- c(theta,runif(42,0,1))
##starting values
S <- 500 #number of iterations
PHI <- matrix(nrow=S, ncol=r)
PHI[1,] <- x
PHI.2 <- matrix(nrow=S, ncol = 3)
PHI.2[1,] <- c(t.2, s.2,phi)
#MH 04.28
PHI.4 <- matrix(nrow=S, ncol = 51)
#matrix of 51 theta’s updated using spatial techniques
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PHI.4[1,] <- theta.n
##Gibbs Sampling
for(s in 2:S) {
cat("s=", s,"\n")
#### phi
ss.x <- sum(x[-r]^2)
s2.s <- t.2/ss.x
mu.t<-sum(x[1:n]*x[2:r])/ss.x
phi <- rnorm(1,mu.t, sqrt(s2.s))
#cat("phi=", phi, "\n")
#### x0
mu.t <- (phi*x[2]/t.2 + mu.0/w.2)/(phi^2/t.2 + 1/w.2)
#posterior mean of x0
s2.s <- 1/(phi^2/t.2 + 1/w.2) #posterior variance of x0
x[1] <- rnorm(1, mu.t, sqrt(s2.s))
#### x1 - x19
s2.s <- 1/((sum(theta.n[1:5]^2)/s.2 + (1+phi^2)/t.2))
#posterior variance of x
for (i in 1:t.0) {
mu.t <- (sum(d[i,1:5]*theta.n[1:5])/s.2 + phi*(x[i+2] + x[i])/t.2)
*s2.s #posterior mean of x
x[i+1] <- rnorm(1, mu.t, sqrt(s2.s)) #sample from the posterior of x
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}#### x20 - x27
s2.s <- 1/((sum(theta.n[1:6]^2)/s.2 + (1+phi^2)/t.2))
for (i in (t.0+1):(t.0+8)) {
mu.t <- (sum(d[i,1:6]*theta.n[1:6])/s.2 + phi*(x[i+2] + x[i])/t.2)
*s2.s
x[i+1] <- rnorm(1, mu.t, sqrt(s2.s))
}
#### x28 - x29
s2.s <- 1/((sum(theta.n[1:9]^2)/s.2 + (1+phi^2)/t.2))
for (i in (t.0+9):(n-1)) {
mu.t <- (sum(d[i,1:9]*theta.n[1:9])/s.2 + phi*(x[i+2] + x[i])/t.2)
*s2.s
x[i+1] <- rnorm(1, mu.t, sqrt(s2.s))
}
#### xn: n=30 (through 2002)
s2.s <- 1/((sum(theta.n[1:9]^2)/s.2 + 1/t.2))
mu.t <- (sum(d[n, 1:9]*theta.n[1:9])/s.2 + (phi*x[n]/t.2))*s2.s
x[n+1] <- rnorm(1, mu.t, sqrt(s2.s))
#### tau.2
mu.t <- (n/2) + a #posterior mean of tau^2
s2.s<-1/(1/b + sum((x[2:r]-phi*x[1:n])^2)/2)
#posterior var of tau^2
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t.2<-rivg(mu.t, s2.s)
#### sigma.2
mu.t <- ((5*n + n - t.0) + 3*(n - (t.0 + 8)))/2 + a
#posterior mean of sigma^2
term<-sum((d[,(1:5)]-outer(x[-1], theta.n[1:5]))^2)
term<-term+sum((d[(t.0+1):n,6] - theta.n[6]*x[(t.0+2):(n+1)])^2)
term<-term+sum((d[(t.0+9):n,7:9]
- outer(x[(t.0+10):(n+1)], theta.n[7:9]))^2)
s2.s <- 1/(term/2 + 1/b) #posterior var of sigma^2
s.2<-rivg(mu.t, s2.s)
#cat("tau_sq=", t.2, "sigma_sq=", s.2,"\n")
#MH 04.28
#no y information available - theta being updated using information
from neighbors - 41 states, theta.10 to theta.51
for(j in 10:51){
mu.t <- sum(n.m[j,3:53]*theta.n)/sum(n.m[j,3:53])
s2.s <- eta.2/sum(n.m[j,3:53])
theta.n[j] <- rnorm(1,mu.t,sqrt(s2.s))
}
#MH 04.28
#update theta 1 - 9 using spatial posterior
#theta 1 - 5
x.sqsum <- sum(x[-1]^2)
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for(j in 1:5){
s2.s <- 1/(x.sqsum/s.2 + (1/eta.2)*sum(n.m[j,3:53]))
mu.t <- ((sum(d[,j]*x[-1]))/s.2 + sum(n.m[j,3:53]*theta.n)/eta.2)
*s2.s
theta.n[j] <- rnorm(1,mu.t,sqrt(s2.s))
}
#### theta 6
x.sqsum <- sum(x[(t.0+2):(n+1)]^2)
s2.s <- 1/(x.sqsum/s.2 + (1/eta.2)*sum(n.m[6,3:53]))
mu.t <- ((sum(d[(t.0+1):n,6]*x[(t.0+2):(n+1)]))/s.2
+ sum(n.m[6,3:53]*theta.n)/eta.2)*s2.s
theta.n[6] <- rnorm(1, mu.t, sqrt(s2.s))
#### theta 7-9
x.sqsum <- sum(x[(t.0+10):(n+1)]^2)
for(j in 7:9){
s2.s <- 1/(x.sqsum/s.2 + (1/eta.2)*sum(n.m[j,3:53]))
mu.t <- ((sum(d[(t.0+9):n, j]*x[(t.0+10):(n+1)]))/s.2
+ sum(n.m[j,3:53]*theta.n)/eta.2)*s2.s
theta.n[j] <- rnorm(1, mu.t, sqrt(s2.s))
}
PHI[s,] <- x
PHI.2[s,] <- c(t.2, s.2, phi)
PHI.4[s,] <- theta.n
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}#Predictions 2003 - 2006
start.i = 5000
end.i = S
N=n
pred.1 <- matrix(nrow=3, ncol=51)
pred.2 <- matrix(nrow=3, ncol=51)
pred.3 <- matrix(nrow=3, ncol=51)
pred.4 <- matrix(nrow=3, ncol=51)
for(i in 1:51){
pred.1[1, i]<-quantile(PHI.4[start.i:end.i, i]
*PHI.2[start.i:end.i, 3]^1*PHI[start.i:end.i, N+1],.025)
pred.1[2, i]<-mean(PHI.4[start.i:end.i, i]
*PHI.2[start.i:end.i, 3]^1*PHI[start.i:end.i, N+1])
pred.1[3, i]<-quantile(PHI.4[start.i:end.i, i]
*PHI.2[start.i:end.i, 3]^1*PHI[start.i:end.i, N+1],.975)
pred.2[1, i]<-quantile(PHI.4[start.i:end.i, i]
*PHI.2[start.i:end.i, 3]^2*PHI[start.i:end.i, N+1],.025)
pred.2[2, i]<-mean(PHI.4[start.i:end.i, i]
*PHI.2[start.i:end.i, 3]^2*PHI[start.i:end.i, N+1])
pred.2[3, i]<-quantile(PHI.4[start.i:end.i, i]
*PHI.2[start.i:end.i, 3]^2*PHI[start.i:end.i, N+1],.975)
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pred.3[1, i]<-quantile(PHI.4[start.i:end.i, i]
*PHI.2[start.i:end.i, 3]^3*PHI[start.i:end.i, N+1],.025)
pred.3[2, i]<-mean(PHI.4[start.i:end.i, i]
*PHI.2[start.i:end.i, 3]^3*PHI[start.i:end.i, N+1])
pred.3[3, i]<-quantile(PHI.4[start.i:end.i, i]
*PHI.2[start.i:end.i, 3]^3*PHI[start.i:end.i, N+1],.975)
pred.4[1, i]<-quantile(PHI.4[start.i:end.i, i]
*PHI.2[start.i:end.i, 3]^4*PHI[start.i:end.i, N+1],.025)
pred.4[2, i]<-mean(PHI.4[start.i:end.i, i]
*PHI.2[start.i:end.i, 3]^4*PHI[start.i:end.i, N+1])
pred.4[3, i]<-quantile(PHI.4[start.i:end.i, i]
*PHI.2[start.i:end.i, 3]^4*PHI[start.i:end.i, N+1],.975)
}
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